Oximidine Ⅲ
$150.99
Oximidine III, a powerful antitumor antibiotic, selectively targets the growth of rat fibroblast 3Y1 cells. With its ability to induce mutations in various tumor genes, this compound is essential for researchers and health professionals seeking effective cancer treatment solutions.
Overview
Oximidine III serves as a vital research compound for healthcare professionals and scientists working in oncology. This antitumor antibiotic is designed to selectively inhibit the growth of rat fibroblast 3Y1 cells, making it a valuable tool in studying cancer mechanisms. Its unique ability to induce mutations in various tumor genes allows for a deeper understanding of cancer biology and treatment approaches.
Key Features
- Targets rat fibroblast 3Y1 cells effectively
- Induces mutations across multiple tumor genes
- Demonstrates varying IC50 values, enhancing its research utility
- Arrests cells with RAS or SRC mutations in the G1 phase of the cell cycle
- Increases expression of p21WAF1, a crucial protein in cell regulation
Specifications
| Property | Value |
|---|---|
| IC50 for vH-ras-3Y1 | 14 nM |
| IC50 for v-src-3Y1 | 4.5 nM |
| IC50 for normal 3Y1 cells | 140 nM |
FAQ
What is Oximidine III used for?
Oximidine III is primarily used in cancer research to study the effects of antitumor antibiotics on tumor cells and gene mutations.
How does Oximidine III affect cell growth?
This compound selectively inhibits the growth of specific cancerous cells, aiding in understanding tumor behavior and potential treatment avenues.
Are there any safety concerns?
As with any research compound, proper handling and adherence to safety protocols are essential. Consult safety data sheets for detailed information.
For those interested in advancing their research, Oximidine III is a must-have addition to your lab supplies. Buy Oximidine III today to enhance your studies in cancer treatment and cellular biology.
Related Products
Browse more in New Arrivals in Health Products.
Related products
New Arrivals in Health Products
